NILK-3801

About LamKap Bio

LamKap Bio is a private, preclinical-stage biotech developing a pipeline of bispecific antibodies targeting solid tumors. Its core technology is the κλ-body platform, which enables the creation of fully human, multispecific antibodies designed to be 'truly natural' to potentially improve safety and efficacy. The company's most advanced program, NILK-2301 (CEA x CD3), has entered Phase 1 clinical trials, positioning it as an emerging player in the competitive T-cell engager and macrophage-redirection space for oncology.

Therapeutic Areas

Other GPC3-expressing solid tumors Drugs